Prospective Observational Study to Describe Characteristics and Management of Patients With Postmenopausal Osteoporosis Treated With Prolia® in Routine Clinical Practice

Number of Participants Receiving an Individual Prescription and Injection of Denosumab From the Initial Prescribing Physician Office by Each Individual Injection

时间窗: Baseline (day 1), and at Months 6, 12, 18 and 24 (corresponding to the first, second, third and fourth post-baseline injections respectively)

Types of Health Care Providers Administering Denosumab at the Fourth Post-baseline Injection

时间窗: Month 24

Types of health care providers administering an individual injection of denosumab inside or outside the initial prescribing office at the fourth post-baseline injection.

Types of Health Care Providers Administering Denosumab at the First Post-baseline Injection

时间窗: Month 6

Types of health care providers administering an individual injection of denosumab inside or outside the initial prescribing office at the first post-baseline injection.

Types of Health Care Providers Administering Denosumab at the Second Post-baseline Injection

时间窗: Month 12

Types of health care providers administering an individual injection of denosumab inside or outside the initial prescribing office at the second post-baseline injection.

Types of Health Care Providers Administering Denosumab at the Third Post-baseline Injection

时间窗: Month 18

Types of health care providers administering an individual injection of denosumab inside or outside the initial prescribing office at the third post-baseline injection.

Number of Denosumab Post-baseline Injections Received by Each Participant

时间窗: 24 months

Number of Participants Receiving All Prescriptions and Injections of Denosumab From the Initial Prescribing Physician's Office

时间窗: 24 months

Number of participants who received all injection(s), including baseline injection, from the initial prescribing site irrespective of total number of injections received on study.

Number of Participants With a Referral by the Prescribing Physician to Other Health Care Providers for Continuation or Follow-up of Care

时间窗: 24 months

Types of Health Care Providers Administering an Individual Injection of Denosumab at the Baseline Injection

时间窗: Baseline (day 1)

Types of health care providers administering an individual injection of denosumab inside or outside the initial prescribing office at the baseline injection.

Number of Participants Having Radiologic Bone Assessments

时间窗: Pre-baseline (before first denosumab injection) and during the study (post-baseline)

Number of participants having radiologic bone assessments pre-treatment with denosumab and during the study.

Number of Participants Having Osteoporosis Related Laboratory Examinations

时间窗: Pre-baseline (before first denosumab injection) and post-baseline

Number of participants having osteoporosis related laboratory examinations pre-treatment with denosumab and during the study. Participants may not have been given denosumab injection when they attended each visit.

Number of Participants Receiving All Prescriptions and Injections of Denosumab

时间窗: Months 6, 12, 18 and 24 (corresponding to the first, second, third and fourth post-baseline injections respectively)

Number of participants receiving all prescriptions and injections of denosumab whether or not the injections are given at the initial prescribing physician's office.